Research Progress in Androgen Receptor and Triple Negative Breast Cancer.
10.3881/j.issn.1000-503X.14943
- Author:
Min-Yu JIA
1
Author Information
1. Department of Palliative Medicine,West China Fourth Hospital of Sichuan University,Chengdu 610000,China.
- Publication Type:Journal Article
- Keywords:
androgen receptor;
androgen receptor antagonist;
triple negative breast cancer;
tumor biomarker
- MeSH:
Humans;
Triple Negative Breast Neoplasms/pathology*;
Receptors, Androgen/metabolism*;
Prognosis;
Biomarkers;
Signal Transduction
- From:
Acta Academiae Medicinae Sinicae
2023;45(2):303-310
- CountryChina
- Language:Chinese
-
Abstract:
The research on androgen receptor (AR) in breast cancer is advancing.Although the prognostic value of AR in triple negative breast cancer (TNBC) is controversial,a variety of studies have demonstrated that the lack of AR expression exacerbates disease progression.Moreover,the TNBC subtype of AR(-) is more aggressive than that of AR(+) due to the lack of prognostic biomarkers and therapeutic targets.With the discovery and deepening research of novel therapeutic targets such as phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin and S-phase kinase-associated protein 2 signaling pathways,as well as the emerging of immunotherapies,the treatment options for TNBC are increasing.Regarding the role of AR in TNBC,the studies about the tumor biology of AR(-)TNBC and novel biomarkers for improved management of the disease remain insufficient.In this review,we summarize the research progress of AR in TNBC,put forward avenues for future research on TNBC,and propose potential biomarkers and therapeutic strategies that warrant investigation.
